Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Specifics About Millennium Sponsored Studies To Be Featured At ASH

Home/Specifics About Millennium Sponsored Studies To Be Featured At ASH

Specifics About Millennium Sponsored Studies To Be Featured At ASH

Yesterday’s article, Pre-American Society Of Hematology (ASH) News Starting To Break, featured the first part of Millennium Pharmaceutical’s Curtainraiser ASH Preview Press Release.

Here is a preview of major studies involving Velcade which will be presented at ASH:

Multiple Myeloma

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)


Presenter: Pieter Sonneveld, M.D., University Hospital, Rotterdam, The Netherlands
Abstract #40: Oral Presentation, Sunday, December 5, 5:15 pm ET


This Phase III head-to-head, randomized study compared VELCADE maintenance to an immunodulatory agent maintenance in the front-line setting.  Endpoints included progression-free survival, overall survival, response and safety.

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients


Presenter: Ruben Niesvizky, M.D., Weill Cornell Medical College, New York, NY
Abstract #619: Oral Presentation, Monday, December 6, 2:45 pm ET


The UPFRONT study is a U.S. community-based, randomized, open-label, multicenter Phase IIIb trial comparing three VELCADE based combinations followed by VELCADE maintenance in front-line multiple myeloma.  Endpoints included profession-free survival, response rate, safety and tolerability.

A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma


Presenter: Philippe Moreau, University Hospital, Nantes, France
Abstract #312: Oral Presentation, Monday, December 6, 8:15 am ET


This multi-center, international, randomized Phase III trial compared intravenous to subcutaneous administration of VELCADE.  Endpoints included response rate, one-year overall survival, duration of response and time to progression.

Of course, Millennium is not only focusing on multiple myeloma.  You can see a preview of research centering on several types of lymphoma and leukemia by going to: American Society Of Hematology Meetings To Feature Latest Advances In Blood Cancer Research.

Lots to cover and lots to learn!  I had better get to work.
Feel good and keep smiling!  Pat